1. Home
  2. BCAB vs KVHI Comparison

BCAB vs KVHI Comparison

Compare BCAB & KVHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • KVHI
  • Stock Information
  • Founded
  • BCAB 2007
  • KVHI 1978
  • Country
  • BCAB United States
  • KVHI United States
  • Employees
  • BCAB N/A
  • KVHI N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • KVHI Radio And Television Broadcasting And Communications Equipment
  • Sector
  • BCAB Health Care
  • KVHI Technology
  • Exchange
  • BCAB Nasdaq
  • KVHI Nasdaq
  • Market Cap
  • BCAB 22.3M
  • KVHI 101.5M
  • IPO Year
  • BCAB 2020
  • KVHI 1996
  • Fundamental
  • Price
  • BCAB $0.39
  • KVHI $5.25
  • Analyst Decision
  • BCAB Buy
  • KVHI
  • Analyst Count
  • BCAB 2
  • KVHI 0
  • Target Price
  • BCAB $1.00
  • KVHI N/A
  • AVG Volume (30 Days)
  • BCAB 550.8K
  • KVHI 23.9K
  • Earning Date
  • BCAB 08-07-2025
  • KVHI 07-31-2025
  • Dividend Yield
  • BCAB N/A
  • KVHI N/A
  • EPS Growth
  • BCAB N/A
  • KVHI N/A
  • EPS
  • BCAB N/A
  • KVHI N/A
  • Revenue
  • BCAB $11,000,000.00
  • KVHI $109,975,000.00
  • Revenue This Year
  • BCAB N/A
  • KVHI $1.02
  • Revenue Next Year
  • BCAB N/A
  • KVHI $12.63
  • P/E Ratio
  • BCAB N/A
  • KVHI N/A
  • Revenue Growth
  • BCAB N/A
  • KVHI N/A
  • 52 Week Low
  • BCAB $0.24
  • KVHI $4.17
  • 52 Week High
  • BCAB $2.53
  • KVHI $6.16
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 52.08
  • KVHI 47.79
  • Support Level
  • BCAB $0.36
  • KVHI $5.23
  • Resistance Level
  • BCAB $0.42
  • KVHI $5.61
  • Average True Range (ATR)
  • BCAB 0.03
  • KVHI 0.20
  • MACD
  • BCAB 0.00
  • KVHI -0.01
  • Stochastic Oscillator
  • BCAB 71.57
  • KVHI 25.49

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About KVHI KVH Industries Inc.

KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.

Share on Social Networks: